Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 39.5% - Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) traded up 39.5% during mid-day trading on Monday . The stock traded as high as $37.83 and last traded at $32.12. 4,420,354 shares traded hands during mid-day trading, an increase of 556% from the average session volume of 674,270 shares. The stock had previously closed at $23.03.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Noble Financial reaffirmed an "outperform" rating and set a $70.00 price objective on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th. StockNews.com initiated coverage on Tonix Pharmaceuticals in a report on Monday, February 10th. They issued a "sell" rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm has a market cap of $37.61 million, a P/E ratio of 0.00 and a beta of 2.23. The stock's 50 day moving average is $18.85 and its two-hundred day moving average is $20.11.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($6.23) by ($3.54). The company had revenue of $2.58 million during the quarter, compared to analyst estimates of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Institutional Trading of Tonix Pharmaceuticals

Several large investors have recently added to or reduced their stakes in TNXP. Commonwealth Equity Services LLC bought a new stake in Tonix Pharmaceuticals during the 4th quarter worth about $40,000. Two Sigma Investments LP bought a new position in Tonix Pharmaceuticals during the fourth quarter worth about $66,000. PFG Investments LLC acquired a new position in Tonix Pharmaceuticals during the fourth quarter valued at approximately $72,000. Northern Trust Corp bought a new stake in shares of Tonix Pharmaceuticals in the 4th quarter valued at $162,000. Finally, Point72 Asset Management L.P. acquired a new position in Tonix Pharmaceuticals in the fourth quarter valued at about $526,000. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.